Japan Chemotherapy induced Nausea and Vomiting Drugs Market was valued at USD 0.38 Billion in 2022 and is projected to reach USD 0.62 Billion by 2030, growing at a CAGR of 6.9% from 2024 to 2030.
The Japan Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market is experiencing significant growth as the demand for effective treatments rises among patients undergoing chemotherapy. These drugs are crucial in managing the debilitating symptoms of nausea and vomiting, common side effects of cancer treatments. The pharmaceutical industry, along with healthcare providers, is continuously seeking advanced therapies to enhance patient well-being and ensure higher compliance with chemotherapy regimens.
Several key types of drugs are available in the Japan CINV drugs market, including serotonin receptor antagonists (5-HT3 inhibitors), NK1 receptor antagonists, corticosteroids, and cannabinoids. Among these, 5-HT3 inhibitors are most commonly used due to their high efficacy in controlling acute nausea and vomiting. However, the recent rise in the use of NK1 receptor antagonists, such as aprepitant, showcases a shift toward more comprehensive treatments that manage both acute and delayed CINV. The market also sees a growing demand for newer drug classes that offer extended relief and improved patient quality of life.
One of the key factors driving the market is the increasing number of cancer patients in Japan, as cancer rates rise, leading to greater reliance on chemotherapy as a treatment option. In fact, according to health industry reports, Japan’s aging population contributes significantly to this trend, with elderly patients being more susceptible to side effects like nausea and vomiting. As a result, the demand for drugs that prevent or mitigate these symptoms has increased dramatically.
The need for chemotherapy-induced nausea and vomiting drugs is not only driven by patient demand but also by the necessity for pharmaceutical companies to innovate and produce more specialized treatments. Industries are now focusing on developing drugs with fewer side effects, quicker onset of action, and longer durations of effect. Research and development are heavily invested in enhancing drug formulations to meet the varied needs of oncology patients.
Furthermore, the growing awareness of CINV management in the healthcare sector and the introduction of supportive care guidelines have further contributed to the rising requirement for these drugs. Hospitals, oncology centers, and other medical facilities in Japan are now more likely to prioritize CINV prevention, ensuring that patients receive the most effective treatment options available.
Get an In-Depth Research Analysis of the Japan Chemotherapy induced Nausea and Vomiting Drugs Market Size And Forecast [2025-2032]
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
Merck
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Japan Chemotherapy induced Nausea and Vomiting Drugs Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Japan Chemotherapy induced Nausea and Vomiting Drugs Market
5-HT3 Receptor Antagonists
NK1 Receptor Antagonists
Corticosteroids
Dopamine Antagonists
Others
Oral
Intravenous
Subcutaneous
Transdermal
Acute Nausea and Vomiting
Delayed Nausea and Vomiting
Anticipatory Nausea and Vomiting
Breakthrough Nausea and Vomiting
Pediatric Patients
Adult Patients
Elderly Patients
Hospital Settings
Home Healthcare
Outpatient Clinics
Long-term Care Facilities
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ Japan Chemotherapy induced Nausea and Vomiting Drugs Market Research Analysis
1. Introduction of the Japan Chemotherapy induced Nausea and Vomiting Drugs Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Japan Chemotherapy induced Nausea and Vomiting Drugs Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Japan Chemotherapy induced Nausea and Vomiting Drugs Market, By Type
6. Japan Chemotherapy induced Nausea and Vomiting Drugs Market, By Application
7. Japan Chemotherapy induced Nausea and Vomiting Drugs Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. Japan Chemotherapy induced Nausea and Vomiting Drugs Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/